0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Neurological Review |

Biomarkers of Alzheimer Disease FREE

John H. Growdon, MD
[+] Author Affiliations

From the Department of Neurology, Massachusetts General Hospital, Boston, Mass.


Section Editor: David E. Pleasure, MD

More Author Information
Arch Neurol. 1999;56(3):281-283. doi:10.1001/archneur.56.3.281.
Text Size: A A A
Published online

A definitive diagnosis of Alzheimer disease (AD) depends on finding widespread neurofibrillary tangles and plentiful neuritic plaques in the brain of an individual with a clinical diagnosis of progressive dementia.1Using contemporary diagnostic criteria, the antemortem diagnosis of probable AD in centers specialized for AD is confirmed 80% to 90% of the time. There is the suspicion, but no firm data, that diagnostic accuracy is much lower outside of practices dedicated to patients with dementia. Furthermore, the diagnostic workup is expensive. In most settings, the evaluation generally includes a careful medical history and physical examination; neurologic examination (and psychiatric consultation as indicated); laboratory blood studies to exclude underlying metabolic and medical illnesses that masquerade as AD; a mental status assessment and formal cognitive tests; and a computed tomographic scan or magnetic resonance imaging of the brain.2Because these procedures are time-consuming and costly, there is a need to identify biological tests that can circumvent aspects of this workup and point the physician to the correct diagnosis. It would be highly desirable to measure a subtance or substances in blood or urine samples or cerebrospinal fluid (CSF) that would lead to a positive diagnosis of AD without the need for specialized dementia clinics and the expense and time of standard diagnostic evaluations. In response to this need, the Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging convened a working group in 1997 to examine the status of various antemortem markers for AD. The consensus statement of this group, entitled "Molecular and Biochemical Markers of AD," was published in 1998.3The consensus statement first defined the characteristics of an ideal biomarker, and then outlined the steps required for a proposed biomarker to achieve acceptance by the medical community. Finally, the statement reviewed the current state of all proposed biological markers. The workshop participants observed that none of the current biomarkers had yet achieved universal acceptance and concluded none fully met the consensus criteria for an ideal marker. Nonetheless, several tests were identified as good markers for familial AD, and several other tests showed promise as a diagnostic aid for sporadic AD. The purpose of this review is to put these recommendations into a practical context. What does the consensus statement tell the practicing clinician? How do the opinions in the consensus statement affect clinical practice in diagnosing and treating patients with dementia?

The most successful diagnostic tests for AD are based on advances in molecular genetics, and are limited to early-onset familial AD. Missense mutations in 3 genes—PS1on chromosome 14, PS2on chromosome 1, and APPon chromosome 21—all cause familial AD. In all, only a few hundred families carry these identified mutations that cause autosomal dominant AD. Most of these pedigrees have PS1mutations and onset of dementia at age younger than 50 years; mutations in the APPgene are rare, and there are only 2 pedigrees with PS2mutations. From a practical viewpoint, it is reasonable to search for a PS1mutation in familial AD with very early onset, but searching for missense mutations in individuals with familial AD with onset older than 50 years or in individuals without a family history of AD is rarely worthwhile. In contrast to these deterministic genetic causes of AD, the apolipoprotein E (apoE) ϵ4 allele is a risk factor for AD. Numerous studies4,5attest to the fact that the ϵ4 allele is 3 to 4 times more common in AD, including the most common category of late-onset disease without known family history, than in individuals who are not demented. As opposed to the missense mutations, however, the ϵ4allele is not a deterministic cause of AD, only a risk factor. Thus, relying on the apoEgenotype alone to establish a diagnosis of AD is inadequate because this measure by itself has low sensitivity and specificity. Many individuals, perhaps a majority, who inherit ϵ4do not develop AD even at an advanced age. Nonetheless, when used in conjunction with conventional diagnostic workup, finding an ϵ4allele adds a small percentage of confidence to the clinical diagnosis.6

Genetics aside, the most convincing diagnostic tests will be those that seek to detect in life the histopathologic hallmarks characteristic of AD that are observed in the brain at death. The neurofibrillary tangle and neuritic plaque are the principal lesions associated with AD. The neurofibrillary tangle is composed primarily of hyperphosphorylated tau, which is a cytoskeletal protein. Diffuse amyloid deposits pepper the AD brain; the mature neuritic plaque contains a compacted core of amyloid protein. Much of this amyloid is a 42-amino acid peptide derived from proteolytic cleavage of a larger amyloid precursor protein molecule. This peptide, called Aβ1-42, has putative neurotoxic properties that may initiate a cascade of events leading to neuronal dysfunction and death.7,8As a result of intense investigation into the mechanism whereby tangles and plaques form, antibodies directed toward epitopes of tau and toward different amyloid fragments have been adapted for clinical use. Under normal conditions, a small amount of soluble Aβ1-42circulates in the bloodstream. In individuals with the deterministic mutations for AD in PS1, PS2, and APP, Aβ1-42levels in the blood are increased compared with levels in sporadic AD, which generally do not differ from levels measured in individuals without dementia.9Although potentially useful in diagnosing familial AD, measuring Aβ1-42levels in the blood is limited to research laboratories and is not in widespread use. Even if this test were widely available, information to date indicates plasma Aβ1-42levels would not be diagnostically useful in most patients with nonfamilial or late-onset AD.

The CSF bathes the brain, and is potentially a more accurate representation of what goes on in the brain than measuring tau or Aβ in the peripheral bloodstream. Both tau and amyloid fragments can be measured in CSF; their detection forms the basis for the development of commercial diagnostic tests for AD. There is general consensus that CSF levels of tau are significantly increased in AD compared with both healthy control subjects and patients with non-AD neurologic diseases.10Similarly, there is general consensus that levels of Aβ1-42are characteristically decreased in AD, whereas levels of Aβ total (Aβ1-42and Aβ1-40) are no different in patients with AD than in control subjects.11The crucial question is whether the increases in tau and decreases in Aβ1-42occur with sufficient frequency and magnitude that they offer diagnostic value. To date, the answer has been no. Both measures suffer from poor accuracy: if sensitivity is set at a satisfactory 80% to 90% level, specificity is low, and vice versa. Combining the 2 measures increase accuracy slightly, but many individual values remain in a diagnostically indeterminate range.10,12A further limitation on using these measures as diagnostic tests is that few cases of dementia with a clinical diagnosis of probable AD and the putative diagnostic profile of low Aβ1-42and high tau in CSF during life have been confirmed pathologically. Other CSF markers, such as neuronal thread protein, have been proposed as biomarkers for AD,13but require independent confirmation. It is likely that refinements on current Aβ1-42, tau, or neuronal thread protein assays will occur as a result of attempts to improve diagnostic accuracy. At present, these tests can be recommended only as an adjunct to comprehensive diagnostic assessment in difficult cases. Confidence in the diagnosis increases when the CSF profile fits that expected in AD, but indeterminate results should be anticipated.

What can we expect from an ideal biomarker for AD? It is probably unrealistic to expect that any biomarker be 100% specific and sensitive for the diagnosis of AD. At autopsy, the brains of many patients with definite AD have other lesions, including infarcts, gliosis, and Lewy bodies. In any given instance, it is difficult to be certain which of these was etiologically important in producing dementia. Clinicians may eventually follow the lead of pathologists, who have adopted a less dichotomous diagnosis of AD vs no AD than in the past. According to the National Institute on Aging and the Reagan Research Institute of the Alzheimer's Association consensus criteria for the neuropathological diagnosis of AD,14the diagnosis of AD is probabilistic. That is to say, the diagnosis of AD is based on a likelihood estimate in which all pathologic findings are described, and the extent and intensity of plaques and tangles graded. If pathologists examining the entire brain are cautious in diagnosing AD unequivocally, then perhaps clinicians, armed with indirect molecular and biochemical measures of plaques and tangles, should be even more reserved. Viewed from this perspective, biological markers of AD may turn out to be more useful in tracking the course of illness and documenting the response to treatment than in diagnosis.

Accepted for publication June 20, 1998.

Corresponding author: John H. Growdon, MD, Department of Neurology, Massachusetts General Hospital, Wang Ambulatory Center, Suite 830, John H. 15 Parkman St, Boston, MA 02114.

McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34939- 944
Link to Article
Growdon  JH Advances in the diagnosis of Alzheimer's disease. Iqbal  KMortimer  JAWinblad  BWisniewski  HMeds.Research Advances in Alzheimer's Disease and Related Disorders. New York, NY John Wiley & Sons Inc1995;139- 153
The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Consensus Report of the Working Group on molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging. 1998;19109- 116
Link to Article
Saunders  AMStrittmatter  WJSchmechel  D  et al.  Association of apolipoprotein E allele ϵ4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;431467- 1472
Link to Article
Gomez-Isla  TWest  HLRebeck  GW  et al.  Clinical and pathological correlates of apolipoprotein E ϵ4 in Alzheimer's disease. Ann Neurol. 1996;3962- 70
Link to Article
Mayeux  RSaunders  AMShea  S  et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med. 1998;338506- 511
Link to Article
Selkoe  DJ Normal and abnormal biology of the β-amyloid precursor protein. Ann Rev Neurosci. 1994;17489- 517
Link to Article
Hardy  J Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20154- 159
Link to Article
Scheuner  DEckman  CJensen  M  et al.  Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2864- 870
Link to Article
Clark  CMEwbank  DLee  VM-YTrojanowski  JQ Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. Growdon  JHRossor  MNeds.The Dementias. Boston, Mass Butterworth-Heinemann1998;285- 304
Motter  RVigo-Pelfrey  CKholodenko  D  et al.  Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38643- 648
Link to Article
Kanai  MMatsubara  EIsoe  K  et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40 and Aβ1-42(43)Ann Neurol. 1998;4417- 26
Link to Article
de la Monte  SMGhanbari  KFrey  WH  et al.  Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest. 1997;1003093- 3104
Link to Article
The National Institute of Aging and Reagan Institute Working Group on diagnostic criteria for the neuropathologic assessment of Alzheimer's disease, Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(suppl 4)S1- S2
Link to Article

Figures

Tables

References

McKhann  GDrachman  DFolstein  MKatzman  RPrice  DStadlan  EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34939- 944
Link to Article
Growdon  JH Advances in the diagnosis of Alzheimer's disease. Iqbal  KMortimer  JAWinblad  BWisniewski  HMeds.Research Advances in Alzheimer's Disease and Related Disorders. New York, NY John Wiley & Sons Inc1995;139- 153
The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Consensus Report of the Working Group on molecular and biochemical markers of Alzheimer's disease. Neurobiol Aging. 1998;19109- 116
Link to Article
Saunders  AMStrittmatter  WJSchmechel  D  et al.  Association of apolipoprotein E allele ϵ4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;431467- 1472
Link to Article
Gomez-Isla  TWest  HLRebeck  GW  et al.  Clinical and pathological correlates of apolipoprotein E ϵ4 in Alzheimer's disease. Ann Neurol. 1996;3962- 70
Link to Article
Mayeux  RSaunders  AMShea  S  et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med. 1998;338506- 511
Link to Article
Selkoe  DJ Normal and abnormal biology of the β-amyloid precursor protein. Ann Rev Neurosci. 1994;17489- 517
Link to Article
Hardy  J Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 1997;20154- 159
Link to Article
Scheuner  DEckman  CJensen  M  et al.  Secreted amyloid B-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2864- 870
Link to Article
Clark  CMEwbank  DLee  VM-YTrojanowski  JQ Molecular pathology of Alzheimer's disease: neuronal cytoskeletal abnormalities. Growdon  JHRossor  MNeds.The Dementias. Boston, Mass Butterworth-Heinemann1998;285- 304
Motter  RVigo-Pelfrey  CKholodenko  D  et al.  Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38643- 648
Link to Article
Kanai  MMatsubara  EIsoe  K  et al.  Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40 and Aβ1-42(43)Ann Neurol. 1998;4417- 26
Link to Article
de la Monte  SMGhanbari  KFrey  WH  et al.  Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J Clin Invest. 1997;1003093- 3104
Link to Article
The National Institute of Aging and Reagan Institute Working Group on diagnostic criteria for the neuropathologic assessment of Alzheimer's disease, Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging. 1997;18(suppl 4)S1- S2
Link to Article

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 63

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

Users' Guides to the Medical Literature
Clinical Resolution

Users' Guides to the Medical Literature
Clinical Scenario